Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.